NCT05420727已完成1 期
Theranostics in Soft Tissue Sarcoma Using a Vascular Disruption Approach
John O. Prior1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2023年2月8日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- imaging result obtained by Ga-68-PSMA-11 PET/CT
研究概览
简要总结
To test the feasibility of theranostic targeting the PSMA receptor in STS patients by Ga-68-PSMA-11 PET/CT and Lu-177-ITG-PSMA-1 treat-ment with special emphasis on vascular disruption using a translational approach.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female or male ≥ 18 years old at the time of informed consent
- •Patients with proven Soft Tissue Sarcoma
- •Patients need to pass the sarcoma tumor board and the molecular tumor board at CHUV and no approved therapeutic alternative is available
- •Progression of the disease by RECIST v1.1 after standard therapies according to the treat-ing oncologists
- •Informed Consent as documented by signed informed consent form
排除标准
- •Patients under active anti-sarcoma treatment other than the study product (Lu-177-ITG-PSMA-1)
- •Female participants who are pregnant or breast feeding
- •Female participants with intention to become pregnant during the course of the study
- •Lack of safe contraception, defined as: Female participants of childbearing potential, not us-ing and not willing to continue using a medically reliable method of contraception for the en-tire study duration until 6 months after last Lu-177-ITG-PSMA-1 treatment, such as oral, in-jectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Male patients of reproductive potential, not using and not willing to use a medically reliable method of contraception for the entire study duration until 6 months after last Lu-177-ITG-PSMA-1 treatment, such as barrier method or sexual abstinence or who are not using any other method considered sufficiently reliable by the investigator in individual cases. The par-ticipant must inform their female partners about the participation in this trial and they must use additional effective contraception (e.g., hormonal) during the trial until 6 months after the last Lu-177-ITG-PSMA-1 treatment.
- •Previous enrolment into the current study
- •History of any disease or relevant physical condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment
- •Insufficient knowledge of project language, inability to give consent or to follow procedures, incapacity to follow radiation safety procedures, required by the study
- •Enrolment of the investigator, his/her family members, employees and other dependent per-sons
- •The patient makes use of his/her "right not to know" and refuses to be informed about inci-dental findings
- •Absence of PSMA accumulation in at least 50% of tumours on Ga-68-PSMA-11 PET/CT
- •Grade IV renal impairment and above (calculated GFR < 30 mL/min/1.73 m2)
- •Blood count disturbance:
- •Platelets < 75,000/µL. Leukocytes < 2,500/µL Haemoglobin < 80 g/L. • Disturbance of liver function with: Total bilirubin > 2 times the upper limit of the norm ASAT/ALAT > 3 times the upper limit without the presence of liver metastases ASAT/ALAT > 5 times the upper limit in the presence of liver metastases
- •Hypersensitivity to any of the ingredients of the injectable product
研究组 & 干预措施
Positive Ga-68-PSMA-11 PET/CT patients treated by Lu-177-ITG-PSMA-1
Experimental
Positive Ga-68-PSMA-11 PET/CT prior to two cycles of Lu-177-ITG-PSMA-1 i scheduled six weeks apart.
干预措施: Ga-68-PSMA-11 PET/CT (Drug)
Positive Ga-68-PSMA-11 PET/CT patients treated by Lu-177-ITG-PSMA-1
Experimental
Positive Ga-68-PSMA-11 PET/CT prior to two cycles of Lu-177-ITG-PSMA-1 i scheduled six weeks apart.
干预措施: Lu-177-ITG-PSMA-1 (Drug)
结局指标
主要结局
imaging result obtained by Ga-68-PSMA-11 PET/CT
时间窗: four weeks after the second cycle of Lu-177-ITG-PSMA-1 treatment, compared to base-line
次要结局
- SUVmax and radiological changes using PSMA - PET/CT(four weeks after the second cycle of Lu-177-ITG-PSMA-1 treatment, compared to base-line.)
- Tumor evaluation using contrast enhanced computed tomography (ceCT)(four weeks after the second cycle of Lu-177-ITG-PSMA-1 treatment, compared to base-line.)
研究者
John O. Prior
Head of Nuclear Medicine Department, PhD MD
University of Lausanne Hospitals
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride CapsuleSoft Tissue SarcomasNCT04223583Henan Cancer Hospital70
已完成
1 期
Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue SarcomaSarcoma, Soft TissueNCT05858710Thermosome GmbH8
终止
2 期
Phase II Study of TAEST16001 in Soft Tissue SarcomaSoft Tissue SarcomaNCT05549921Sun Yat-sen University8
已完成
1 期
Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic SarcomaSarcomaNCT03123276Royal Marsden NHS Foundation Trust25
进行中（未招募）
2 期
Neoadjuvant Intralesional Injection of Talimogene LaherparepvecNCT06660810John Rieth2